Table 1. Summary of Trial Characteristics.
| Trial characteristics | No. (%) |
|---|---|
| Total | 286 |
| Trial phase | |
| 2 | 126 (44.1) |
| 3 | 103 (36.0) |
| Unspecified | 57 (19.9) |
| Arms | |
| 2 | 262 (91.6) |
| ≥3 | 24 (8.4) |
| Size of trial, No. of participants | |
| Small (<100) | 106 (37.1) |
| Intermediate (100-500) | 117 (40.9) |
| Large (>500) | 63 (22.0) |
| Clinical setting | |
| Localized | 43 (15.0) |
| Biochemical recurrence | 11 (3.8) |
| Metastatic, castration-sensitive | 61 (21.3) |
| Metastatic, castration-resistant | 161 (56.3) |
| Othera | 10 (3.5) |
| Class of treatment regimenb | |
| Antiandrogen | 141 (49.3) |
| Chemotherapy | 105 (36.7) |
| LHRH agonist/antagonist | 28 (9.8) |
| Liquid radiation | 8 (2.8) |
| Immunotherapy | 6 (2.1) |
| PARPi | 3 (1.0) |
| Primary end point | |
| OS | 58 (20.3) |
| PFS | 48 (16.8) |
| Other | 112 (39.2) |
| Unspecified | 68 (23.8) |
| Positive trial | |
| Yes | 92 (32.2) |
| No | 113 (39.5) |
| Unclear | 81 (28.3) |
| Funding source | |
| Industry | 166 (58.0) |
| Nonindustry | 100 (35.0) |
| Unspecified | 20 (7.0) |
| Center | |
| Single-center | 28 (9.8) |
| Multicenter | 245 (85.7) |
| Unspecified | 13 (4.5) |
| Regional recruitment | |
| US only | 65 (22.7) |
| International with US recruitment | 62 (21.7) |
| Excluding US | 115 (40.2) |
| Region unspecified | 44 (15.4) |
Abbreviations: LHRH, luteinizing hormone-releasing hormone; PARPi, polyadenosine diphosphate ribose polymerase inhibitor; OS, overall survival; PFS, progression-free survival.
a
Other clinical settings: all stages (n = 7), asymptomatic (n = 1), relapsed (n = 1), unspecified-metastatic (n = 1).
b
Total percentages exceed 100% due to some trials having multiple classes of treatment in their experimental arm.